Class summary at a glance.

Every drug in the Protease Inhibitor class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 3tracked in Part D
CY24 Part D spend: $90.0Mcombined across class
Total Rx claims: 109K19K unique beneficiaries
Generic mfrs (active): 14across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Darunavir

Brand: PREZISTA · 92K Part D claims (CY24) · 16K beneficiaries · First FDA approval: 2008-03-08

10 generic mfrs 0 plans require PA

Low NADAC$1.13

→

Avg plan cost$5.94

Part D spend $81.7M 5× spread, current vs floor

Class share

91%

of class CY24 spend

View profile →

Atazanavir

Brand: Atazanavir Sulfate · 16K Part D claims (CY24) · 3K beneficiaries · First FDA approval: 2003-06-24

4 generic mfrs 0 plans require PA Discontinued

Low NADAC$1.09

→

Avg plan cost$1.89

Part D spend $6.8M 2× spread, current vs floor

Class share

of class CY24 spend

View profile →

Tipranavir

Brand: Aptivus · 708 Part D claims (CY24) · 98 beneficiaries · First FDA approval: 2005-07-01

Brand-only (no generics) 0 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $1.5M

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.